- •
Atypical hemolytic uremic syndrome is a rare form of thrombotic microangiopathy resulting from chronic uncontrolled activation of the alternative pathway of complement.
- •
Untreated, it carries a high degree of morbidity and mortality.
- •
Atypical hemolytic uremic syndrome is associated with nonimmune hemolytic anemia, thrombocytopenia, and renal involvement; it is distinguished from thrombotic thrombocytopenic purpura and Shigatoxin-positive Escherichia coli hemolytic uremic syndrome.
- •
Atypical
Atypical Hemolytic Uremic Syndrome
Section snippets
Key points
Epidemiology
The estimated annual incidence of atypical HUS in children less than 18 years of age is approximately 1.0 to 3.3 per million.6, 7, 8 Atypical HUS occurs with equal frequency in boys and girls when onset occurs during childhood. In the global atypical HUS registry of 516 registered patients of all ages, 39% of patients developed the disease before 18 years of age.9 Approximately 44% of children experienced their first episode before the age of 2 years. Atypical HUS may be sporadic or familial,
Clinical presentation
In children, the onset of atypical HUS is usually abrupt, although up to 20% of patients may present with slowly progressive symptoms. In 191 patients registered on the International Registry of Recurrent and Familial HUS/TTP for whom data were available, underlying complement amplifying conditions/diseases were present in 69% of patients (Fig. 3).10 Diarrhea/gastroenteritis and upper respiratory tract infections were associated with atypical HUS in 42% of patients, whereas a variety of other
Pathophysiology
The pathogenesis of atypical HUS stems from genetic or acquired defects in the regulation of the alternative complement pathway. This pathway (Fig. 4) is constitutively active in plasma by the hydrolysis of the reactive thioester bond of C3 to C3(H2O), a process known as the tickover mechanism, where it can bind to Factor B. Factor B when bound to C3(H2O) is a substrate for Factor D, and is cleaved to its fragments Bb, which remains a part of the molecular complex, and Ba. The complex C3(H2O)Bb
Laboratory diagnosis
Laboratory features of atypical HUS are listed in Box 2. Clinically, atypical HUS is characterized by hemolytic anemia and consumptive thrombocytopenia. Endothelial damage and thrombosis in the microvasculature result in abnormally high shear stress leading to platelet aggregation and mechanical (nonimmune) red cell destruction. Thrombocytopenia is modest with platelet counts uncommonly less than 30 × 109/L. Examination of the peripheral blood smear characteristically demonstrates fragmented
Thrombotic Thrombocytopenic Purpura
Atypical HUS can usually be distinguished from TTP based on the clinical presentation and laboratory features. In general, more modest laboratory evidence of renal impairment would be most consistent with TTP, although great caution must be exercised in applying this paradigm because the severity of individual organ system involvement in atypical HUS can vary greatly from patient to patient. An analysis of multiple cohorts of adult patients has yielded the insight that if thrombocytopenia is
Plasma Therapy
There is no evidence that plasma therapy (plasma infusion or plasmapheresis) affects the ultimate outcome of children or adults with atypical HUS. In a large study of more than 270 patients enrolled in an international registry of atypical HUS, plasma therapy was shown to induce hematologic remission in up to 78% of episodes in children and 53% in adults. Nevertheless, at 3 years of follow-up 48% of children and 67% of adults had end-stage renal disease or had died.10 Similarly, in a French
References (61)
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome
Transfus Med Rev
(2014)- et al.
Haemolytic uraemic syndrome
Lancet
(2017) - et al.
Skin involvement in atypical hemolytic uremic syndrome
Am J Kidney Dis
(2014) - et al.
How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome
Blood
(2014) - et al.
von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura
Blood
(2002) - et al.
An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura
J Thromb Haemost
(2013) - et al.
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
Blood
(2006) - et al.
Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP
Blood
(2014) - et al.
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
Blood
(2015) - et al.
Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies
Immunobiology
(2017)
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
Blood
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Kidney Int
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
Kidney Int
Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab
Am J Kidney Dis
Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy
Blood
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases
Am J Kidney Dis
Eculizumab cessation in atypical hemolytic uremic syndrome
Blood
Atypical hemolytic-uremic syndrome
N Engl J Med
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
N Engl J Med
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
N Engl J Med
Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome
Semin Thromb Hemost
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document
Nefrologia
Atypical hemolytic uremic syndrome
Orphanet J Rare Dis
The global aHUS registry: methodology and initial patient characteristics
BMC Nephrol
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
Clin J Am Soc Nephrol
Thromboctopenia is not mandatory to diagnose haemolytic and uremic syndrome
BMC Nephrol
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome
J Am Soc Nephrol
Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement
Pediatr Nephrol
Peripheral gangrene in children with atypical hemolytic uremic syndrome
Pediatrics
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
Nat Genet
Cited by (26)
Thrombotic microangiopathies in critically ill children: The MATUCIP registry in Spain
2023, Anales de PediatriaThrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
2021, Journal of PediatricsCitation Excerpt :Our 3 patients developed TMA approximately 1 week after administration, suggesting an immune-mediated etiology. Other causes and presentations of TMA include hemolytic uremic syndrome resulting from shiga toxin-positive E coli; thrombotic thrombocytopenic purpura resulting from a reduction of ADAMTS13, the protease that cleaves von Willebrand factor (vWF); hereditary deficiencies in regulation of coagulation or alternative complement pathways3; and a wide variety of infectious pathogens, including encapsulated organisms.6 In addition to exposure to onasemnogene abeparvovec, each of the 3 patients had contributory factors that could be putatively associated with TMA.
Hemolytic Uremic Syndrome
2019, Pediatric Clinics of North AmericaCitation Excerpt :Penetrance of the disease is incomplete, with approximately 50% of family members who carry the mutation not manifesting with disease by age 45 years, across all disease-associated genes.43 There are 3 main mechanisms of complement dysregulation attributed to disease pathogenesis: loss of function mutations in complement regulatory proteins, such as Factor H, Factor I, Membrane Cofactor Protein (CD46), and thrombomodulin; gain of function mutations in effector proteins, such as Factor B or C3; and formation of neutralizing autoantibodies against Factor H.44 However, up to 30% of patients have no demonstrable mutation in the known disease-associated genes.5 The resulting complement dysregulation leads to increased C3b deposition on the endothelial cell surface, resulting in increased formation of the potent proinflammatory anaphylatoxin C5a and the lytic terminal complement complex C5b-9,4 leading to endothelial injury and TMA.
The chemical and laboratory investigation of hemolysis
2019, Advances in Clinical ChemistryCitation Excerpt :Shiga-toxin-positive Escherichia coli or other toxin-positive bacterial infection leading to hemolytic uremic syndrome (detected by identification of Shiga-toxin producing bacteria by microbiological studies) [86]; Congenital complement component or Factor H/Factor I/Factor B mutations associated with atypical hemolytic uremic syndrome (assessed by targeted molecular assays or gene sequencing) [87]; Acquired or congenital ADAMTS13 deficiency, associated with TTP (ADAMTS13 and possible associated inhibitors of this enzyme can be readily assessed by FRET-based testing and other assays) [88];
A Renal Disease Triggered by COVID-19
2024, Clinical Pediatrics
Conflict of Interest: Dr R.A. Gruppo has received honoraria for speaking engagements from Alexion Pharmaceuticals. Dr B. Dixon has received honoraria for speaking engagements from Alexion Pharmaceuticals, and has served as a consultant for Alexion Pharmaceuticals and Achillion Pharmaceuticals.